Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial

•There is a paucity of data on end-stage kidney disease (ESKD) in hypertension.•We investigated patients with high-risk hypertension aged 50–80 years or above.•On valsartan 47 patients (0.61 %) and on amlodipine 50 patients (0.66 %) developed ESKD.•Achieved SBP ≥135 mmHg relates to ESKD (n = 73/8766...

Full description

Saved in:
Bibliographic Details
Published in:European journal of internal medicine 2024-12
Main Authors: Olsen, Eirik, Jamerson, Kenneth, Schmieder, Roland E., Søraas, Camilla L., Mariampillai, Julian E., Mancia, Giuseppe, Kjeldsen, Sverre E., Heimark, Sondre, Mehlum, Maria H., Liestøl, Knut, Larstorp, Anne C.K., Halvorsen, Lene V., Høieggen, Aud, Burnier, Michel, Rostrup, Morten, Julius, Stevo, Weber, Michael A.
Format: Article
Language:English
Subjects:
Amlodipine
Blood pressure
Cardiovascular disease
Hypertension
Kidney failure
Valsartan
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•There is a paucity of data on end-stage kidney disease (ESKD) in hypertension.•We investigated patients with high-risk hypertension aged 50–80 years or above.•On valsartan 47 patients (0.61 %) and on amlodipine 50 patients (0.66 %) developed ESKD.•Achieved SBP ≥135 mmHg relates to ESKD (n = 73/8766 patients, 0.8 %).•Achieved SBP
ISSN:0953-6205
1879-0828
1879-0828
DOI:10.1016/j.ejim.2024.12.021